Clinical and laboratory characteristics of chronic hepatitis C on the early stages of development
https://doi.org/10.24884/1607-4181-2016-23-4-45-59
Abstract
Aim of the research – to assess the clinical and laboratory parameters in patients with chronic hepatitis C (CHC) on the early stages of development and their comparison with the level of galectin3. The study included 78 patients with oligosymptomatic course of the disease and minimal liver fibrosis in the most cases. In the most patients with stages of the disease exceeding 8 years, viral load was over a million copies/ml. In 10 % of patients on the early stages of the disease, changes corresponding to severe liver fibrosis and cirrhosis F3 and F4 were detected. Moderate correlation of ALT activity, viral load and low severity with the duration of the disease was identified. There is a trend towards a higher level of galectin3 in a long course of CHC in comparison with earlier stages of its development, with significantly higher average level of galectin-3 in patients with minimal liver fibrosis (F0–F1) as compared to advanced stages, suggesting its importance in the launching and initial mechanisms of fibrogenesis.
About the Authors
N. S. Zhevnerova
Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Competing Interests: нет конфликта интересов
T. V. Antonova
Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Competing Interests: нет конфликта интересов
V. A. Kovaleva
Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова
Russian Federation
Competing Interests: нет конфликта интересов
Russian Federation
Competing Interests: нет конфликта интересов
References
1. Вельков В. В. Сывороточные биомаркеры фиброза печени: до свидания, биопсия? – М.: Lomonosoff Print, 2009. – 40 с.
2. Драпкина О. М., Деева Т. А. Прогностическоезначение определения уровня галектина-3 у пациентов с метаболическим синдромом и неалкогольной жировой болезнью печени // Кардиоваскулярная терапия и профилактика. – 2015. –Т. 14. – № 5. – С. 40–47.
3. Павлов Ч. С., Глушенков Д. В., Ивашкин В. Т. Современные возможности эластометрии, Фибро и АктиТеста в диагностике фиброза печени //Росс. журн. гастроэнтерол., гепатол., колопроктол. – 2008. – Т. 18. – № 4. – С. 43–52.
4. Friedman S. L.Liver fibrosis – from bench to bedside // J. Hepatol. – 2003. – № 38. – Suppl. 1. – P. 38–53.
5. Henderson N. S., Maskinnon A. C., Farnworsh S. L. et al. Galectin3 regulates myofibroblast activation in hepatic fibrosis// Proc. Natl. Acad. Sci USA. – 2006. – Vol. 103 (13). – P. 5060–5065.
6. Hope V. D.Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association / V. D. Hope, I. Eramova, D. Capurro, M. C. Donoghoe // Epidemiol. Infect. – 2014. – Vol. 142. – № 2. – P. 270–286.
7. Kramer F.Galectin3: clinical utility and prognostic value in patients with heart failure// Reasearch Reports in Clinical Cardiology. – 2013. – № 4. – P. 13–12.
8. Lee U. E., Friedman S. L.Mechanisms of Hepatic Fibrogenesis // Best Pract. Res. Clin. Gastroenterol. – 2011. – Vol. 25. –№ 2. – P. 195–206.
9. Yang RiYao, Rabinovich Gabriel A, Liu Fu-Tong. Galectins: structure, function and therapeutic potential // Expert Reviews in Molecular Medicine, Published online. – 2008. – Vol. 10. DOI: http://dx.doi.org/10.1017/S1462399408000719.
Review
For citations:
Zhevnerova N.S., Antonova T.V., Kovaleva V.A. Clinical and laboratory characteristics of chronic hepatitis C on the early stages of development. The Scientific Notes of the Pavlov University. 2016;23(4):45-59. (In Russ.) https://doi.org/10.24884/1607-4181-2016-23-4-45-59
Views:
908
Email this article 